ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag hiv art policy quotes genetics genomics

3D virus cells attacking a DNA strand
HIV DNA Circularizes to Bypass CRISPR-Based Treatments
Nele Haelterman, PhD | Mar 7, 2022 | 3 min read
CRISPR-mediated removal of HIV can create small, infectious DNA molecules.
Cas9 enzyme
Molecular Glue ‘Shreds’ Cas9 and Enables a New Form of CRISPR Control
Ida Emilie Steinmark, PhD | Apr 26, 2023 | 3 min read
In a bid to address safety concerns about immune reactions during treatment with CRISPR-based therapeutics, a new technique speeds up how quickly the body destroys the DNA-cutting enzyme Cas9.
Toward a “Clickable Plant”
Jane Salodof Macneil | Feb 15, 2004 | 9 min read
By conscious design, plant genomics initiatives have devoted initial resources to new technology development. Part of that money went to developing functional genomics approaches, and part to new sequencing technologies.
Sequencing Stakes: Celera Genomics Carves Its Niche
Ricki Lewis | Jul 18, 1999 | 8 min read
J. Craig Venter is no stranger to contradiction and controversy. He seems to thrive on it. In 1991, when the National Institutes of Health was haggling over patenting expressed sequence tags (ESTs)--a shortcut to identifying protein-encoding genes--Venter the inventor accepted a private offer to found The Institute for Genomic Research (TIGR) in Rockville, Md. TIGR would discover ESTs and give most of them to a commercial sibling, Human Genome Sciences (HGS), to market. ESTs are now a standard
Genetic Testing For Cancer Presents Complex Challenges
Ricki Lewis | Oct 12, 1997 | 8 min read
HARD NUMBERS: Penn's Fergus Couch evaluated the "actual prevelance of BRCA1 mutations" among 263 women with a family history of the disease. In the early days of the Human Genome Project, attention focused on rare disorders that strictly follow Mendel's laws of inheritance, recurring in predictable patterns within families. With many of these genes identified and mapped as the finish line nears, emphasis has shifted to genes that cause more common ills, particularly cancers, and the public has
Genome Investigator Craig Venter Reflects On Turbulent Past And Future Ambitions
Karen Young Kreeger | Jul 23, 1995 | 8 min read
And Future Ambitions Editor's Note: For the past four years, former National Institutes of Health researcher J. Craig Venter has been a major figure in the turbulent debates and scientific discoveries surrounding the study of genes and genomes. Events heated up in 1991, when NIH attempted to patent gene fragments, which were isolated using Venter's expressed sequence tag (EST)/complementary DNA (cDNA) approach for discovering human genes (M.A. Adams et al., Science, 252:1651-6, 1991). NIH's mo
Privatizing the Human Genome?
Paul Smaglik | Jun 7, 1998 | 10 min read
Principals behind joint-venture proposal and public effort seek to define relationships A private effort to sequence the human genome four years ahead of the Human Genome Project's 2005 goal could either compete directly with the federal project or meld seamlessly with it. Before any relationship between the two efforts becomes formalized, scientists and federal officials involved with the Human Genome Project must determine whether the private approach will work, who will own the data, how qu
Will Genomics Spoil Gene Ownership?
Douglas Steinberg | Sep 3, 2000 | 8 min read
Consider a scenario for the year 2002: Using commercially available software, bioprospector "Craig Collins" spends a day scavenging the Human Genome Project (HGP) database for the alternatively spliced genes prized by Wall Street. He enters the sequences of several candidate genes into a software package that prints out the likely functions of their protein products. One protein looks like it could be pharmaceutical paydirt, so he isolates the corresponding cDNA, inserts it into a vector, then
Single Nucleotide Polymorphisms: Big Pharma Hedges its Bets
Eugene Russo | Jul 18, 1999 | 7 min read
SNP CENTRAL: A genetics researcher takes to the bench at the Wellcome Trust's Sanger Centre in Cambridge, England. The sequencing center and its London sponsor provided key leadership in the SNP Consortium, a public-private venture to find and map 300,000 single nucleotide polymorphisms. The Wellcome Trust helped entice 10 pharmaceutical firms to join the consortium by putting up $14 million of the project's estimated $45 million price tag. The Sanger Centre will provide much of the radiation h
Deviations From The Norm: Systems For Mutation Detection Reveal Hidden Potentials
Kailash Gupta | Jul 18, 1999 | 10+ min read
Date: July 19, 1999Mutation Detection Systems and Methods Affymetrix's p53 chip Researchers leading the Human Genome Project (HGP) originally envisioned completion of the entire genome sequence (approximately 3 billion base pairs) by the year 2005. Recently the arena of human genome sequencing has seen a lot of heat generated by the entry of both commercial entrepreneurs and public consortia. Celera, a company formed by highly skilled and competent commercial organizations (TIGR and Perkin-Elm

Run a Search

ADVERTISEMENT